Nanogen s $31.5 Million Placement Tops Tank With Enough Capital for 15 Quarters, CFO Says | GenomeWeb

With last week’s placement of approximately $33.7 million in Nanogen stock, and its cash on hand, the San Diego-based company now estimates it has nearly five years of financial fuel available to commercialize its NanoChip electronic microarray platform.

Nanogen, which was founded in 1993 and went public in 1998, netted the funds with the sale of 4.25 million shares of common stock to institutional investors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.